Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Free Full Text Free
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Fenske, D. B.
Right arrow Articles by Cullis, P. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fenske, D. B.
Right arrow Articles by Cullis, P. R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Liposomal Nanomedicines: An Emerging Field

David B. Fenske1, Arcadio Chonn2 and Pieter R. Cullis3

1 Department of Chemistry, University College of the Fraser Valley, Abbotsford, British Columbia, Canada
2 Advanced Integrated MicroSystems Ltd., West Vancouver, British Columbia, Canada
3 Centre for Drug Research and Development, University of British Columbia, Vancouver, British Columbia, Canada

Correspondence: Address correspondence to: Pieter R. Cullis, FRSC, Department of Biochemistry and Molecular Biology, Life Sciences Centre, 2350 Health Sciences Mall, University of British Columbia, Vancouver, BC, Canada V6T 1Z3; e-mail: pieterc{at}interchange.ubc.ca.

Liposomal nanoparticles (LNs) encapsulating therapeutic agents, or liposomal nanomedicines (LNMs), represent one of the most advanced classes of drug delivery systems, with several currently on the market and many more in clinical trials. During the past 20 years, a variety of techniques have been developed for encapsulating both conventional drugs and the new genetic drugs (plasmid DNA–containing therapeutic genes, anti-sense oligonucleotides, and small, interfering RNA [siRNA]) within LNs encompassing a very specific set of properties: a diameter centered on 100 nm, a high drug-to-lipid ratio, excellent retention of the encapsulated drug, and a long (> 6 hours) circulation lifetime. Particles with these properties tend to accumulate at sites of disease, such as tumors, where the endothelial layer is "leaky" and allows extravasation of particles with small diameters. Thus, LNs protect the drug during circulation, prevent it from reaching healthy tissues, and permit its accumulation at sites of disease. We will discuss recent advances in this field involving conventional anticancer drugs as well as gene-delivery, immunostimulatory, and gene-silencing applications involving the new genetic drugs. LNMs have the potential to offer new treatments in such areas as cancer therapy, vaccine development, and cholesterol management.

Key Words: Liposomal nanoparticles • drug delivery • enhanced permeation and retention • gene therapy • antisense oligonucleotides • siRNA

Abbreviations: APC, antigen presenting cells • CHOP, chemotherapy treatment composed of cyclophosphamide, doxorubicin, vincristine, and prednisone • CpG, unmethylated CpG dinucleotides • DODAC, N, N-dioleyl-N, N-dimethylammonium chloride • DODAP, 1, 2-dioleoyl-3-(dimethylamino)propane • DODMA, 1, 2-dioleyloxy-N, N-dimethyl-3-aminopropane • DOPE, dioleoylphos-phatidylethanolamine • dsRNA, double-strand RNA • LN, liposomal nanoparticle • LNM, liposomal nanomedicine • MLVs, multilamellar vesicles • NK, natural killer • ODNs, oligodeoxynucleotides • PEG, poly(ethylene glycol) • PEGCerC14, PEG-ceramide containing 14 carbon fatty acid • PEGCerC20, PEG-ceramide containing 20 carbon fatty acid • PEG-S-DSG, PEG covalently bonded to distearoylglycerol • RISC, RNA-induced silencing complex • RNAi, RNA interference • SALP, stabilized antisense lipid particles • siRNA, small, interfering RNA • SNALP, stabilized nucleic acid lipid particles • SPLP, stabilized plasmid lipid particles • ssRNA, single-strand RNA • SVP, spontaneous vesicle formation • TLR, toll-like receptors

Toxicologic Pathology, Vol. 36, No. 1, 21-29 (2008)
DOI: 10.1177/0192623307310960


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?